Advertisement

Comparison of the Bactericidal Activities and Post-Antibiotic Effects of the Des-F(6)-Quinolone BMS-284756, Levofloxacin, and Ciprofloxacin Against Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus

  • B. Ryan
  • C. Mazzucco
  • L. Lawrence
  • H. Ho
  • G. Warr
  • J. Barrett
  • M. Frosco
Article

Abstract.

The bactericidal activities and post-antibiotic effects of BMS-284756 (T-3811ME), levofloxacin, and ciprofloxacin were evaluated against a methicillin-susceptible and a methicillin-resistant Staphylococcus aureus strain. Minimum inhibitory concentrations (MICs), minimum bactericidal concentrations, post-antibiotic effects, and post-antibiotic sub-MIC effects were determined and time-kill studies were performed for BMS-284756, levofloxacin, and ciprofloxacin. At 4-times and 10-times the MIC, time-kill kinetics over 3 h and over 24 h were similar for all three quinolones when effects were considered as multiples of the MIC. All three quinolones achieved a 3 log10 reduction in cfu/ml within 2 h. At 10-times the MIC, the post-antibiotic effects of BMS-284756, levofloxacin, and ciprofloxacin were 1.6–2.6 h for the methicillin-susceptible Staphylococcus aureus strain and 1.5–1.9 h for the methicillin-resistant Staphylococcus aureus strain. When actual concentrations were considered, BMS-284756 achieved results comparable to levofloxacin and ciprofloxacin at concentrations nearly 10-fold less. When relating the pharmacokinetic properties of the three quinolones to their in vitro activities, the resulting Cmax/MIC and AUC/MIC ratios were, respectively, 120–240.7 and 1,321.7–2,643 for BMS-284756, 22.8 and 190 for levofloxacin, and 5.9–11.9 and 54.8–109.6 for ciprofloxacin. The greater in vitro activity and favorable human pharmacokinetics of BMS-284756 may translate to improved clinical effectiveness of this agent compared to currently marketed quinolones.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag 2002

Authors and Affiliations

  • B. Ryan
    • 1
  • C. Mazzucco
    • 1
  • L. Lawrence
    • 1
  • H. Ho
    • 1
  • G. Warr
    • 1
  • J. Barrett
    • 2
  • M. Frosco
    • 1
  1. 1.Bristol-Myers Squibb Pharmaceutical Research Institute, Infectious Diseases, Department of Microbiology, 5 Research Parkway, Wallingford, CT 06492USA
  2. 2.Merck & Co. Inc., Merck Research Labs, RYBOY-315, 126 E. Lincoln Avenue, Rahway, NJ 07065-0900USA

Personalised recommendations